Rivaroxaban found noninferior to enoxaparin in acutely ill

February 7, 2013
Rivaroxaban found noninferior to enoxaparin in acutely ill
In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, according to a study published in the Feb. 7 issue of the New England Journal of Medicine.

(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, according to a study published in the Feb. 7 issue of the New England Journal of Medicine.

Alexander T. Cohen, M.D., from King's College Hospital in London, and colleagues randomly assigned 8,101 patients (40 years of age and older) with reduced mobility and an acute requiring hospitalization to receive subcutaneous (40 mg once daily) for 10 days and oral placebo for 35 days, or subcutaneous placebo for 10 days and oral rivaroxaban (10 mg once daily) for 35 days.

At day 10, the researchers found that 2.7 percent of the rivaroxaban group and 2.7 percent of the enoxaparin group experienced asymptomatic proximal or symptomatic venous (relative risk, 0.97; P = 0.003 for non-inferiority). At day 35, 4.4 percent of the rivaroxaban group and 5.7 percent of the enoxaparin group experienced this outcome (relative risk, 0.77; P = 0.02). Major or clinically relevant non-major bleeding occurred in a significantly greater percentage of the rivaroxaban group both at day 10 (2.8 versus 1.2 percent) and at day 35 (4.1 versus 1.7 percent).

"The efficacy of standard-duration rivaroxaban was similar to that of enoxaparin, whereas the efficacy of extended-duration rivaroxaban was superior to that of enoxaparin," Cohen and colleagues conclude. "However, rivaroxaban was associated with an increased risk of clinically relevant bleeding."

The study was funded by Bayer, manufacturer of rivaroxaban, and Janssen, marketer of rivaroxaban; several authors disclosed to pharmaceutical companies, including Bayer and Janssen.

Explore further: More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin

More information: Full Text (subscription or payment may be required)

Related Stories

More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin

October 22, 2012
Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.

Novel drug in pill form safer than standard approach to treat blocked lung blood vessels

March 26, 2012
A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism – a blockage of lung blood vessels usually caused by a clot ...

Higher risk of VTE in CKD surgical patients on enoxaparin

June 8, 2012
(HealthDay) -- For patients with chronic kidney disease (CKD) who undergo total hip replacement (THR), the rate of major venous thromboembolism (VTE) is significantly higher in those treated with enoxaparin compared to those ...

Anti-clotting drug lowers risks in acute coronary syndrome treatment

November 14, 2011
An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American ...

Stroke risk high when anti-clotting drugs stopped

April 25, 2012
Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Study shows ability of new agent to prevent strokes in patients with atrial fibrillation

August 10, 2011
In the primary result from the largest double-blind study ever completed to assess a drug's effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting ...

Recommended for you

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.